← 產業報告目錄

HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-02-28頁數 274報告編號 MD5067

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global HIV diagnostics market is projected to reach USD 5.31 Billion by 2030 from USD 3.25 Billion in 2025, at a CAGR of 10.3% during the forecast period. The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent. Government-led health initiatives and widespread public awareness campaigns encouraging early HIV testing are key drivers of market growth. Additionally, continuous advancements in rapid testing technologies, along with the increasing availability and affordability of self-testing kits, are improving patient compliance and boosting adoption rates. The expansion of diagnostic laboratories, integration of artificial intelligence in diagnostics, and growing collaborations between healthcare organizations and private entities further contribute to market expansion. However, certain challenges may hinder growth, including the high cost of diagnostic tests, limited access to healthcare in remote regions, and a shortage of skilled professionals to conduct and interpret tests. Regulatory hurdles and concerns regarding the accuracy and reliability of some testing methods also pose potential barriers. Despite these challenges, the HIV diagnostics market is expected to experience steady growth, driven by increasing awareness, improved healthcare infrastructure, rising government funding for HIV screening programs, and the growing demand for fast, convenient, and highly accurate testing solutions. The increasing focus on early detection and timely intervention, combined with technological innovations in point-of-care testing, is likely to create significant opportunities for market players in the coming years. “The consumables segment accounted for the largest share of the market in 2024, by product.” The HIV diagnostics market is classified by product type into consumables, instruments, and software & services. In 2024, the consumables segment dominated the market, driven by the recurring demand from laboratories and hospitals, the rising prevalence of HIV/AIDS, and government initiatives supporting the development of advanced consumables. “The confirmatory tests segment accounted for the largest share of the market in 2024, by test type.” By test type, the market is segmented into screening tests, confirmatory tests, and monitoring tests. The monitoring tests segment held the largest share in 2024 and is expected to grow at the highest CAGR. This growth is fueled by increasing awareness of HIV testing, a high volume of monitoring test samples, and the expansion of diagnostic laboratories specializing in HIV/AIDS testing. Additionally, advancements in monitoring test kits are further accelerating the segment’s expansion. “Diagnostic Laboratories segment dominated the HIV diagnostics market in 2024, based on end user.” The HIV diagnostics market is segmented by end users into diagnostic laboratories, hospitals, blood banks, home care settings, and others. In 2024, diagnostic laboratories accounted for the largest market share, driven by the increasing prevalence of HIV/AIDS, the expansion of diagnostic facilities, the rising demand for sample testing, and advancements in point-of-care (POC) technology. The HIV diagnostics market is segmented into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2024, North America led the global market, driven by factors such as the rising prevalence of HIV/AIDS, advancements in point-of-care (POC) diagnostic instruments and test kits, growing awareness initiatives, and an increase in blood transfusions and donations. The presence of well-established healthcare infrastructure, significant investments in research and development, and supportive government policies further contributed to the region's market dominance. However, the Asia Pacific region is projected to experience the highest compound annual growth rate during the forecast period. This rapid expansion is fueled by the rising number of HIV cases, the increasing availability of advanced POC diagnostic products, and growing healthcare investments in emerging economies. Additionally, government-led initiatives promoting HIV awareness, improved healthcare accessibility, and a surge in global market players expanding their presence in the region are further accelerating market growth. The region’s increasing focus on early disease detection, combined with technological advancements and growing collaborations between public and private healthcare organizations, is expected to create significant opportunities for market expansion. The break-up of the profile of primary participants in the HIV diagnostics market: • By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 – 20% • By Designation: M-level - 30%, D-level - 50%, and Others - 20% • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Others-4% The key players in this market are are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others. Research Coverage:  This research report categorizes the HIV diagnostics market by device type (consumables, instruments, software & services ), by test type (screening tests, confirmatory tests, monitoring tests and other HIV diagnostic tests), by end user (diagnostic laboratories, blood banks, home care settings, hospitals and other endusers), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the HIV diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the HIV diagnostics market. Competitive analysis of upcoming startups in the HIV diagnostics market ecosystem is covered in this report. Reasons to buy this report: The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HIV diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (Rising prevalence of HIV/AIDS, Increasing number of blood transfusions & blood donations, Advantages offered by POC diagnostic kits & instruments) opportunities (Growth opportunities in emerging economies), restraints (high cost of NATs), and challenges (lack of skilled workforce) influencing the growth of the HIV diagnostics market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the HIV diagnostics market. • Market Development: Comprehensive information about lucrative markets – the report analyses the HIV diagnostics market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HIV diagnostics market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain).
目錄 Table of Contents
1 INTRODUCTION 27 1.1 STUDY OBJECTIVES 27 1.2 MARKET DEFINITION 27 1.3 MARKET SCOPE 28 1.3.1 MARKET SEGMENTATION 28 1.3.2 INCLUSIONS & EXCLUSIONS 29 1.3.3 YEARS CONSIDERED 30 1.3.4 CURRENCY CONSIDERED 30 1.4 STAKEHOLDERS 30 1.5 SUMMARY OF CHANGES 31 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 2.1.1 SECONDARY DATA 33 2.1.1.1 Key data from secondary sources 34 2.1.2 PRIMARY DATA 35 2.1.2.1 Primary sources 35 2.1.2.2 Key industry insights 36 2.1.2.3 Key data from primary sources 36 2.1.2.4 Breakdown of primary interviews 37 2.2 MARKET SIZE ESTIMATION 37 2.2.1 BOTTOM-UP APPROACH 38 2.2.1.1 Approach 1: Company revenue estimation approach 38 2.2.1.2 Approach 2: Presentations of companies and primary interviews 38 2.2.1.3 Growth forecast 39 2.2.1.4 CAGR projections 39 2.2.2 TOP-DOWN APPROACH 40 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 40 2.4 MARKET SHARE ASSUMPTIONS 41 2.5 STUDY ASSUMPTIONS 42 2.6 RESEARCH LIMITATIONS 42 2.7 RISK ASSESSMENT 43 3 EXECUTIVE SUMMARY 44 4 PREMIUM INSIGHTS 47 4.1 HIV DIAGNOSTICS MARKET OVERVIEW 47 4.2 GEOGRAPHIC GROWTH OPPORTUNITIES 50 5 MARKET OVERVIEW 51 5.1 INTRODUCTION 51 5.2 MARKET DYNAMICS 51 5.2.1 DRIVERS 52 5.2.1.1 Rising prevalence of HIV/AIDS 52 5.2.1.2 Increasing number of blood transfusions & blood donations 53 5.2.1.3 Advantages offered by POC diagnostic kits & instruments 53 5.2.1.4 Increasing initiatives for HIV awareness campaigns 54 5.2.2 RESTRAINTS 56 5.2.2.1 High cost of NATs 56 5.2.3 OPPORTUNITIES 56 5.2.3.1 High growth potential of emerging economies 56 5.2.3.2 Trend of self-testing and growing preference for at- home diagnostic kits 57 5.2.4 CHALLENGES 57 5.2.4.1 Operational barriers and shortage of skilled laboratory technicians 57 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 58 5.4 PRICING ANALYSIS 58 5.4.1 AVERAGE SELLING PRICE OF HIV DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023 59 5.4.2 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021−2023 59 5.4.3 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021−2023 (USD) 60 5.5 VALUE CHAIN ANALYSIS 60 5.6 SUPPLY CHAIN ANALYSIS 62 5.7 ECOSYSTEM ANALYSIS 63 5.8 TECHNOLOGY ANALYSIS 64 5.8.1 KEY TECHNOLOGIES 64 5.8.1.1 ELISA 64 5.8.2 COMPLEMENTARY TECHNOLOGIES 64 5.8.2.1 Western blot tests 64 5.8.3 ADJACENT TECHNOLOGIES 64 5.8.3.1 PCR 64 5.9 INVESTMENT & FUNDING SCENARIO 65 5.10 PATENT ANALYSIS 66 5.11 TRADE ANALYSIS 68 5.11.1 IMPORT DATA FOR HS CODE 3822 68 5.11.2 EXPORT DATA FOR HS CODE 3822 68 5.12 KEY CONFERENCES & EVENTS, 2025–2026 69 5.13 CASE STUDY ANALYSIS 70 5.13.1 ROLE OF COMMUNITY-BASED ORGANIZATIONS (CBOS) IN SUPPORTING PEOPLE WITH HIV 70 5.13.2 MANAGING HIGH BLOOD PRESSURE AND BLOOD SUGAR IN HIV-POSITIVE PATIENTS 71 5.14 REGULATORY LANDSCAPE 72 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.14.2 REGULATORY FRAMEWORK 73 5.14.2.1 North America 73 5.14.2.1.1 US 73 5.14.2.1.2 Canada 73 5.14.2.2 Europe 74 5.14.2.3 Asia Pacific 75 5.14.2.3.1 China 75 5.14.2.3.2 Japan 75 5.14.2.3.3 India 75 5.14.2.4 Latin America 76 5.14.2.4.1 Brazil 76 5.14.2.4.2 Mexico 76 5.14.2.5 Middle East 76 5.14.2.6 Africa 77 5.15 PORTER’S FIVE FORCES ANALYSIS 77 5.15.1 THREAT OF NEW ENTRANTS 78 5.15.2 THREAT OF SUBSTITUTES 78 5.15.3 BARGAINING POWER OF BUYERS 78 5.15.4 BARGAINING POWER OF SUPPLIERS 78 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 79 5.16 KEY STAKEHOLDERS & BUYING CRITERIA 79 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 5.16.2 KEY BUYING CRITERIA, BY PRODUCT 80 5.17 IMPACT OF AI/GENERATIVE AI ON HIV DIAGNOSTICS MARKET 80 5.17.1 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS 80 5.17.2 AI USE CASES 81 5.17.3 COMPANY IMPLEMENTATION OF AI 82 5.17.4 FUTURE OF AI/GENERATIVE AI 83 6 HIV DIAGNOSTICS MARKET, BY TEST TYPE 84 6.1 INTRODUCTION 85 6.2 SCREENING TESTS 86 6.2.1 RAPID TESTS 88 6.2.1.1 Provision of quick test results and ability to diagnose HIV antibodies to fuel uptake 88 6.2.2 ELISA 90 6.2.2.1 Wide applications across infectious disease diagnostics to drive market 90 6.2.3 OTHER SCREENING TESTS 92 6.3 CONFIRMATORY TESTS 94 6.3.1 WESTERN BLOT TESTS 97 6.3.1.1 Gold standard testing for result validation to drive market 97 6.3.2 OTHER CONFIRMATORY TESTS 99 6.4 MONITORING TESTS 101 6.4.1 VIRAL LOAD TESTS 103 6.4.1.1 Accurate provision of quantitative data on HIV infections to boost demand 103 6.4.2 CD4 TESTS 105 6.4.2.1 Ability to number CD4 T lymphocyte cells to support market growth 105 6.5 OTHER HIV DIAGNOSTIC TESTS 107 7 HIV DIAGNOSTICS MARKET, BY PRODUCT 110 7.1 INTRODUCTION 111 7.1.1 CONSUMABLES 112 7.1.2 ASSAY KITS & REAGENTS 114 7.1.2.1 Recurrent purchase to fuel market 114 7.1.3 OTHER CONSUMABLES 117 7.2 INSTRUMENTS 119 7.2.1 RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 119 7.3 SOFTWARE & SERVICES 122 7.3.1 INCREASING DEMAND FOR VALUE-ADDED SERVICES & AUTOMATED SOFTWARE TO SUPPORT MARKET GROWTH 122 8 HIV DIAGNOSTICS MARKET, BY END USER 125 8.1 INTRODUCTION 126 8.2 DIAGNOSTIC LABORATORIES 126 8.2.1 HIGH VOLUME OF HIV TESTING SAMPLES TO PROPEL MARKET 126 8.3 HOSPITALS 129 8.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND FAVORABLE REIMBURSEMENTS TO DRIVE MARKET 129 8.4 BLOOD BANKS 131 8.4.1 RISING NUMBER OF BLOOD DONATIONS TO BOOST DEMAND 131 8.5 HOME CARE SETTINGS 133 8.5.1 INCREASING PREFERENCE FOR AT-HOME TESTING KITS TO SUPPORT MARKET GROWTH 133 8.6 OTHER END USERS 136   9 HIV DIAGNOSTICS MARKET, BY REGION 138 9.1 INTRODUCTION 139 9.2 NORTH AMERICA 139 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 140 9.2.2 US 144 9.2.2.1 High healthcare expenditure to drive market 144 9.2.3 CANADA 147 9.2.3.1 Increasing number of HIV infections and blood donations to drive market 147 9.3 EUROPE 149 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 153 9.3.2 GERMANY 153 9.3.2.1 Favorable government healthcare policies and reimbursements for HIV testing to drive market 153 9.3.3 UK 156 9.3.3.1 Rising government support for HIV awareness campaigns to support market growth 156 9.3.4 FRANCE 159 9.3.4.1 High prevalence of HIV/AIDS to boost demand 159 9.3.5 ITALY 162 9.3.5.1 Increasing number of blood donors to support market growth 162 9.3.6 SPAIN 164 9.3.6.1 Rising adoption of NAT technology to propel market 164 9.3.7 REST OF EUROPE 167 9.4 ASIA PACIFIC 170 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 171 9.4.2 CHINA 174 9.4.2.1 Rising incidence of infectious diseases & HIV to propel market 174 9.4.3 JAPAN 177 9.4.3.1 Growing adoption of advanced HIV screening technologies to drive market 177 9.4.4 INDIA 180 9.4.4.1 Government initiatives such as free HIV testing to drive market 180 9.4.5 REST OF ASIA PACIFIC 183 9.5 LATIN AMERICA 185 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 186 9.5.2 BRAZIL 189 9.5.2.1 Increasing uptake of technologically advanced blood screening tests to drive market 189 9.5.3 MEXICO 191 9.5.3.1 Rising establishment of blood banks to support market growth 191 9.5.4 REST OF LATIN AMERICA 194   9.6 MIDDLE EAST & AFRICA 197 9.6.1 RISING NUMBER OF HIV DIAGNOSTICS AND SURGICAL PROCEDURES TO FUEL MARKET 197 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 200 9.7 GCC COUNTRIES 200 9.7.1 RISING FOCUS ON HIV TESTING AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 200 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 203 10 COMPETITIVE LANDSCAPE 204 10.1 OVERVIEW 204 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 204 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIV DIAGNOSTICS MARKET 204 10.3 REVENUE ANALYSIS, 2021–2023 206 10.4 MARKET SHARE ANALYSIS, 2023 207 10.4.1 RANKING OF KEY MARKET PLAYERS 209 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 209 10.5.1 STARS 209 10.5.2 EMERGING LEADERS 209 10.5.3 PERVASIVE PLAYERS 210 10.5.4 PARTICIPANTS 210 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 211 10.5.5.1 Company footprint 211 10.5.5.2 Region footprint 212 10.5.5.3 Product footprint 213 10.5.5.4 End-user footprint 213 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 214 10.6.1 PROGRESSIVE COMPANIES 214 10.6.2 RESPONSIVE COMPANIES 214 10.6.3 DYNAMIC COMPANIES 214 10.6.4 STARTING BLOCKS 214 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 215 10.6.5.1 Detailed list of key startups/SME players 215 10.6.5.2 Competitive benchmarking of key startups/SMEs 216 10.7 COMPANY VALUATION & FINANCIAL METRICS 217 10.8 BRAND/PRODUCT COMPARISON 218 10.9 COMPETITIVE SCENARIO 218 10.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 218 10.9.2 PRODUCT LAUNCHES & APPROVALS 218 10.9.3 DEALS 220 10.9.4 EXPANSIONS 221 10.9.5 OTHER DEVELOPMENTS 221 11 COMPANY PROFILES 222 11.1 KEY PLAYERS 222 11.1.1 ABBOTT 222 11.1.1.1 Business overview 222 11.1.1.2 Products/Services offered 223 11.1.1.3 Recent developments 225 11.1.1.3.1 Deals 225 11.1.1.4 MnM view 225 11.1.1.4.1 Key strengths 225 11.1.1.4.2 Strategic choices 225 11.1.1.4.3 Weaknesses & competitive threats 226 11.1.2 SIEMENS HEALTHINEERS 227 11.1.2.1 Business overview 227 11.1.2.2 Products/Services offered 228 11.1.2.3 Recent developments 229 11.1.2.3.1 Product/Service launches & approvals 229 11.1.2.3.2 Deals 230 11.1.2.3.3 Other developments 230 11.1.2.4 MnM view 230 11.1.2.4.1 Key strengths 230 11.1.2.4.2 Strategic choices 230 11.1.2.4.3 Weaknesses & competitive threats 230 11.1.3 GRIFOLS, S.A. 231 11.1.3.1 Business overview 231 11.1.3.2 Products/Services offered 233 11.1.3.3 Recent developments 234 11.1.3.3.1 Deals 234 11.1.3.4 MnM view 234 11.1.3.4.1 Key strengths 234 11.1.3.4.2 Strategic choices 234 11.1.3.4.3 Weaknesses & competitive threats 234 11.1.4 DANAHER CORPORATION 235 11.1.4.1 Business overview 235 11.1.4.2 Products/Services offered 236 11.1.4.3 Recent developments 237 11.1.4.3.1 Product launches & approvals 237 11.1.4.3.2 Deals 238 11.1.4.3.3 Expansions 238 11.1.4.4 MnM view 238 11.1.4.4.1 Key strengths 238 11.1.4.4.2 Strategic choices 238 11.1.4.4.3 Weaknesses & competitive threats 239 11.1.5 THERMO FISHER SCIENTIFIC INC. 240 11.1.5.1 Business overview 240 11.1.5.2 Products/Services offered 241 11.1.5.3 Recent developments 242 11.1.5.3.1 Product/Service launches & approvals 242 11.1.5.3.2 Deals 243 11.1.5.4 MnM view 243 11.1.5.4.1 Key strengths 243 11.1.5.4.2 Strategic choices 244 11.1.5.4.3 Weaknesses & competitive threats 244 11.1.6 BIO-RAD LABORATORIES, INC. 245 11.1.6.1 Business overview 245 11.1.6.2 Products/Services offered 246 11.1.6.2.1 Deals 247 11.1.7 F. HOFFMANN-LA ROCHE LTD. 248 11.1.7.1 Business overview 248 11.1.7.2 Products/Services offered 249 11.1.7.3 Recent developments 250 11.1.7.3.1 Product launches & approvals 250 11.1.7.3.2 Deals 250 11.1.7.3.3 Expansions 251 11.2 OTHER PLAYERS 252 11.2.1 BIOMÉRIEUX 252 11.2.2 HOLOGIC, INC. 253 11.2.3 QIAGEN 254 11.2.4 BD 255 11.2.5 TRINITY BIOTECH 256 11.2.6 ORASURE TECHNOLOGIES, INC. 257 11.2.7 BIOSYNEX SA 258 11.2.8 WONDFO 259 11.2.9 GETEIN BIOTECH, INC. 260 11.2.10 MERIL LIFE SCIENCES PVT. LTD. 261 11.2.11 ACCUBIOTECH CO., LTD. 261 11.2.12 BIOLYTICAL LABORATORIES INC. 262 11.2.13 BIO LAB DIAGNOSTICS (I) PRIVATE LIMITED 262 11.2.14 ALPINE BIOMEDICALS PVT LTD. 263 11.2.15 MOLBIO DIAGNOSTICS PVT. LTD. 263 11.2.16 FORTRESS DIAGNOSTICS 264 11.2.17 ADVACARE PHARMA (ACCUQUIK) 265 11.2.18 ADALTIS S.R.L. 265   12 APPENDIX 266 12.1 DISCUSSION GUIDE 266 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 270 12.3 CUSTOMIZATION OPTIONS 272 12.4 RELATED REPORTS 272 12.5 AUTHOR DETAILS 273
圖表清單 List of Tables & Figures
TABLE 1 HIV DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 29 TABLE 2 HIV DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 43 TABLE 3 NUMBER OF PEOPLE LIVING WITH HIV VS. NEW HIV CASES, BY REGION (2023) 52 TABLE 4 AVERAGE SELLING PRICE OF HIV DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2023 59 TABLE 5 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021−2023 59 TABLE 6 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021−2023 (USD) 60 TABLE 7 HIV DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 63 TABLE 8 HIV DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2023–2024 67 TABLE 9 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019–2023 (USD MILLION) 68 TABLE 10 EXPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019–2023 (USD MILLION) 68 TABLE 11 HIV DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026 69 TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 16 EUROPE: CLASSIFICATION OF DEVICES 74 TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75 TABLE 18 HIV DIAGNOSTICS MARKET: PORTER’S FIVE FORCES 78 TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 79 TABLE 20 KEY BUYING CRITERIA FOR PRODUCTS, BY RANK 80 TABLE 21 COMPANY IMPLEMENTATION OF AI IN HIV DIAGNOSTICS MARKET 82 TABLE 22 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 85 TABLE 23 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (MILLION TESTS) 85 TABLE 24 US: HIV DIAGNOSTICS MARKET, BY RAPID TEST TYPE, 2022–2030 (MILLION TESTS) 86 TABLE 25 US: HIV DIAGNOSTICS MARKET, BY CONFIRMATORY TEST TYPE, 2022–2030 (MILLION TESTS) 86 TABLE 26 HIV DIAGNOSTICS MARKET FOR SCREENING TESTS, BY TYPE, 2022–2030 (USD MILLION) 86 TABLE 27 SCREENING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 87 TABLE 28 NORTH AMERICA: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 87 TABLE 29 EUROPE: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 87 TABLE 30 ASIA PACIFIC: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 88 TABLE 31 LATIN AMERICA: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 88 TABLE 32 RAPID TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 89 TABLE 33 NORTH AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 89 TABLE 34 EUROPE: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 89 TABLE 35 ASIA PACIFIC: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 90 TABLE 36 LATIN AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 90 TABLE 37 ELISA MARKET, BY REGION, 2022–2030 (USD MILLION) 91 TABLE 38 NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 91 TABLE 39 EUROPE: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 91 TABLE 40 ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 92 TABLE 41 LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 92 TABLE 42 OTHER SCREENING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 93 TABLE 43 NORTH AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 93 TABLE 44 EUROPE: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 93 TABLE 45 ASIA PACIFIC: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 94 TABLE 46 LATIN AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 94 TABLE 47 CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 95 TABLE 48 CONFIRMATORY TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 95 TABLE 49 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 95 TABLE 50 EUROPE: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 96 TABLE 51 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 96 TABLE 52 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 96 TABLE 53 WESTERN BLOT TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 97 TABLE 54 NORTH AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 97 TABLE 55 EUROPE: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 98 TABLE 56 ASIA PACIFIC: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 98 TABLE 57 LATIN AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 98 TABLE 58 OTHER CONFIRMATORY TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 99 TABLE 59 NORTH AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 99 TABLE 60 EUROPE: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 100 TABLE 61 ASIA PACIFIC: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 100 TABLE 62 LATIN AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 100 TABLE 63 MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 101 TABLE 64 MONITORING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 101 TABLE 65 NORTH AMERICA: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 66 EUROPE: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 67 ASIA PACIFIC: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 68 LATIN AMERICA: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 103 TABLE 69 VIRAL LOAD TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 103 TABLE 70 NORTH AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 71 EUROPE: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 72 ASIA PACIFIC: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 73 LATIN AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 74 CD4 TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 105 TABLE 75 NORTH AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 106 TABLE 76 EUROPE: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 106 TABLE 77 ASIA PACIFIC: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 106 TABLE 78 LATIN AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 107 TABLE 79 OTHER HIV DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2030 (USD MILLION) 108 TABLE 80 NORTH AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 108 TABLE 81 EUROPE: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 108 TABLE 82 ASIA PACIFIC: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 109 TABLE 83 LATIN AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 109 TABLE 84 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 111 TABLE 85 HIV DIAGNOSTICS MARKET FOR CONSUMABLES MARKET, BY TYPE, 2022–2030 (USD MILLION) 112 TABLE 86 HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2022–2030 (USD MILLION) 112 TABLE 87 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 88 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 89 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 90 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 114 TABLE 91 ASSAY KITS & REAGENTS OFFERED BY KEY PLAYERS 115 TABLE 92 ASSAY KITS & REAGENTS MARKET, BY REGION, 2022–2030 (USD MILLION) 115 TABLE 93 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116 TABLE 94 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116 TABLE 95 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116 TABLE 96 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 97 OTHER CONSUMABLES MARKET, BY REGION, 2022–2030 (USD MILLION) 117 TABLE 98 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 99 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 100 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 101 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 119 TABLE 102 KEY INSTRUMENTS AVAILABLE IN HIV DIAGNOSTICS MARKET 120 TABLE 103 HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022–2030 (USD MILLION) 120 TABLE 104 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 105 EUROPE: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 106 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 107 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 122 TABLE 108 HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2030 (USD MILLION) 123 TABLE 109 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 123 TABLE 110 EUROPE: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 124 TABLE 111 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 124 TABLE 112 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION) 124 TABLE 113 HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 126 TABLE 114 DIAGNOSTIC LABORATORIES MARKET, BY REGION, 2022–2030 (USD MILLION) 127 TABLE 115 NORTH AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 116 EUROPE: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 128 TABLE 117 ASIA PACIFIC: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 128 TABLE 118 LATIN AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 128 TABLE 119 HOSPITALS MARKET, BY REGION, 2022–2030 (USD MILLION) 129 TABLE 120 NORTH AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 121 EUROPE: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 122 ASIA PACIFIC: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 123 LATIN AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 131 TABLE 124 BLOOD BANKS MARKET, BY REGION, 2022–2030 (USD MILLION) 132 TABLE 125 NORTH AMERICA: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 126 EUROPE: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 127 ASIA PACIFIC: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 133 TABLE 128 LATIN AMERICA: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 133 TABLE 129 HOME CARE SETTINGS MARKET, BY REGION, 2022–2030 (USD MILLION) 134 TABLE 130 NORTH AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 134 TABLE 131 EUROPE: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 132 ASIA PACIFIC: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 133 LATIN AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 134 OTHER END USERS MARKET, BY REGION, 2022–2030 (USD MILLION) 136 TABLE 135 NORTH AMERICA: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 136 TABLE 136 EUROPE: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 137 TABLE 137 ASIA PACIFIC: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 137 TABLE 138 LATIN AMERICA: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 137 TABLE 139 HIV DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION) 139 TABLE 140 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 140 TABLE 141 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 141 TABLE 142 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 141 TABLE 143 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 141 TABLE 144 NORTH AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 142 TABLE 145 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 142 TABLE 146 NORTH AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 142 TABLE 147 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 143 TABLE 148 US: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 144 TABLE 149 US: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 145 TABLE 150 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 145 TABLE 151 US: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 145 TABLE 152 US: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 146 TABLE 153 US: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 146 TABLE 154 US: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 146 TABLE 155 CANADA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 147 TABLE 156 CANADA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 147 TABLE 157 CANADA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 148 TABLE 158 CANADA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 148 TABLE 159 CANADA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 148 TABLE 160 CANADA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 149 TABLE 161 CANADA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 149 TABLE 162 EUROPE: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 163 EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 150 TABLE 164 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 151 TABLE 165 EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 151 TABLE 166 EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 151 TABLE 167 EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 152 TABLE 168 EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 152 TABLE 169 EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 152 TABLE 170 GERMANY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 154 TABLE 171 GERMANY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 154 TABLE 172 GERMANY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 154 TABLE 173 GERMANY: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155 TABLE 174 GERMANY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155 TABLE 175 GERMANY: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155 TABLE 176 GERMANY: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 156 TABLE 177 UK: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 157 TABLE 178 UK: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 157 TABLE 179 UK: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 157 TABLE 180 UK: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 158 TABLE 181 UK: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 158 TABLE 182 UK: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 158 TABLE 183 UK: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 159 TABLE 184 FRANCE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 159 TABLE 185 FRANCE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 160 TABLE 186 FRANCE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 160 TABLE 187 FRANCE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 160 TABLE 188 FRANCE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 161 TABLE 189 FRANCE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 161 TABLE 190 FRANCE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 161 TABLE 191 ITALY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 162 TABLE 192 ITALY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 162 TABLE 193 ITALY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 163 TABLE 194 ITALY: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 163 TABLE 195 ITALY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 163 TABLE 196 ITALY: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 164 TABLE 197 ITALY: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 164 TABLE 198 SPAIN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 165 TABLE 199 SPAIN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 165 TABLE 200 SPAIN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 165 TABLE 201 SPAIN: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166 TABLE 202 SPAIN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166 TABLE 203 SPAIN: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166 TABLE 204 SPAIN: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 167 TABLE 205 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 167 TABLE 206 REST OF EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 168 TABLE 207 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 168 TABLE 208 REST OF EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 168 TABLE 209 REST OF EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 169 TABLE 210 REST OF EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 169 TABLE 211 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 169 TABLE 212 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 171 TABLE 213 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 171 TABLE 214 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 172 TABLE 215 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 172 TABLE 216 ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 172 TABLE 217 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 173 TABLE 218 ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 173 TABLE 219 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 173 TABLE 220 CHINA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 174 TABLE 221 CHINA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 175 TABLE 222 CHINA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 175 TABLE 223 CHINA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 175 TABLE 224 CHINA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 225 CHINA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 226 CHINA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 176 TABLE 227 JAPAN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 177 TABLE 228 JAPAN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 178 TABLE 229 JAPAN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 178 TABLE 230 JAPAN: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 178 TABLE 231 JAPAN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 179 TABLE 232 JAPAN: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 179 TABLE 233 JAPAN: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 179 TABLE 234 INDIA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 180 TABLE 235 INDIA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 181 TABLE 236 INDIA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 181 TABLE 237 INDIA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 181 TABLE 238 INDIA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 182 TABLE 239 INDIA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 182 TABLE 240 INDIA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 182 TABLE 241 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 183 TABLE 242 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 183 TABLE 243 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 184 TABLE 244 REST OF ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 184 TABLE 245 REST OF ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 184 TABLE 246 REST OF ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 247 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 185 TABLE 248 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 186 TABLE 249 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 186 TABLE 250 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 187 TABLE 251 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 187 TABLE 252 LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 187 TABLE 253 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 188 TABLE 254 LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 188 TABLE 255 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 188 TABLE 256 BRAZIL: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 189 TABLE 257 BRAZIL: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 189 TABLE 258 BRAZIL: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 190 TABLE 259 BRAZIL: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 260 BRAZIL: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 261 BRAZIL: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 191 TABLE 262 BRAZIL HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 191 TABLE 263 MEXICO: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 192 TABLE 264 MEXICO: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 192 TABLE 265 MEXICO: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 192 TABLE 266 MEXICO: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 193 TABLE 267 MEXICO: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 193 TABLE 268 MEXICO: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 193 TABLE 269 MEXICO: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 194 TABLE 270 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 194 TABLE 271 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 272 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 195 TABLE 273 REST OF LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 274 REST OF LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 196 TABLE 275 REST OF LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 196 TABLE 276 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 196 TABLE 277 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 197 TABLE 278 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 279 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 198 TABLE 280 MIDDLE EAST & AFRICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 281 MIDDLE EAST & AFRICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 282 MIDDLE EAST & AFRICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 283 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 199 TABLE 284 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 200 TABLE 285 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 201 TABLE 286 GCC COUNTRIES: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 201 TABLE 287 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 201 TABLE 288 GCC COUNTRIES: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 202 TABLE 289 GCC COUNTRIES: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 202 TABLE 290 GCC COUNTRIES: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 202 TABLE 291 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 203 TABLE 292 GCC COUNTRIES: MACROECONOMIC INDICATORS 203 TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIV DIAGNOSTICS MARKET 204 TABLE 294 HIV DIAGNOSTICS MARKET: DEGREE OF COMPETITION 207 TABLE 295 HIV DIAGNOSTICS MARKET: REGION FOOTPRINT 212 TABLE 296 HIV DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 213 TABLE 297 HIV DIAGNOSTICS MARKET: END-USER FOOTPRINT 213 TABLE 298 HIV DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 215 TABLE 299 HIV DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 216 TABLE 300 HIV DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025 218 TABLE 301 HIV DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2025 220 TABLE 302 HIV DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025 221 TABLE 303 HIV DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 221 TABLE 304 ABBOTT: COMPANY OVERVIEW 222 TABLE 305 ABBOTT: PRODUCTS/SERVICES OFFERED 223 TABLE 306 ABBOTT: DEALS, JANUARY 2021–JANUARY 2025 225 TABLE 307 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 227 TABLE 308 GRIFOLS, S.A.: COMPANY OVERVIEW 231 TABLE 309 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED 233 TABLE 310 GRIFOLS, S.A.: DEALS, JANUARY 2021– JANUARY 2025 234 TABLE 311 DANAHER: COMPANY OVERVIEW 235 TABLE 312 DANAHER: PRODUCTS/SERVICES OFFERED 236 TABLE 313 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 237 TABLE 314 DANAHER: DEALS, JANUARY 2021–JANUARY 2025 238 TABLE 315 DANAHER: EXPANSIONS, JANUARY 2021–JANUARY 2025 238 TABLE 316 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 240 TABLE 317 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 241 TABLE 318 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 242 TABLE 319 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−JANUARY 2025 243 TABLE 320 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 245 TABLE 321 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 246 TABLE 322 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021– JANUARY 2025 247 TABLE 323 F. HOFFMANN-LA ROCHE LTD..: COMPANY OVERVIEW 248 TABLE 324 F. HOFFMANN-LA ROCHE LTD..: PRODUCTS/SERVICES OFFERED 249 TABLE 325 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 250 TABLE 326 F. HOFFMANN-LA ROCHE LTD..: DEALS, JANUARY 2021– JANUARY 2025 250 TABLE 327 F. HOFFMANN-LA ROCHE LTD..: EXPANSIONS, JANUARY 2021– JANUARY 2025 251 TABLE 328 BD: COMPANY OVERVIEW 255 TABLE 329 TRINITY BIOTECH: COMPANY OVERVIEW 256 TABLE 330 BIOSYNEX SA: COMPANY OVERVIEW 258 TABLE 331 GETEIN BIOTECH, INC.: COMPANY OVERVIEW 260 TABLE 332 ADALTIS S.R.L.: COMPANY OVERVIEW 265 _ FIGURE 1 MARKETS & REGIONS COVERED 28 FIGURE 2 HIV DIAGNOSTICS MARKET: RESEARCH DESIGN 32 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 37 FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 38 FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39 FIGURE 6 HIV DIAGNOSTICS MARKET: TOP-DOWN APPROACH 40 FIGURE 7 DATA TRIANGULATION METHODOLOGY 41 FIGURE 8 HIV DIAGNOSTICS MARKET: STUDY ASSUMPTIONS 42 FIGURE 9 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 44 FIGURE 10 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 45 FIGURE 11 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 45 FIGURE 12 HIV DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 46 FIGURE 13 INCREASING PREVALENCE OF HIV AND RISING BLOOD DONATIONS TO PROPEL MARKET 47 FIGURE 14 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 47 FIGURE 15 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 16 HIV DIAGNOSTICS SCREENING TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 17 HIV DIAGNOSTICS CONFIRMATORY TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 49 FIGURE 18 HIV DIAGNOSTICS MONITORING TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 49 FIGURE 19 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50 FIGURE 20 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 50 FIGURE 21 HIV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 FIGURE 22 NEW REVENUE POCKETS FOR PLAYERS IN HIV DIAGNOSTICS MARKET 58 FIGURE 23 HIV DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 61 FIGURE 24 HIV DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 62 FIGURE 25 HIV DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 63 FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2018–2025 65 FIGURE 27 HIV DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 66 FIGURE 28 HIV DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 77 FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 79 FIGURE 30 KEY BUYING CRITERIA, BY PRODUCT 80 FIGURE 31 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS 81 FIGURE 32 HIV DIAGNOSTICS MARKET SEGMENTATION, BY PRODUCT 111 FIGURE 33 NORTH AMERICA: HIV DIAGNOSTICS MARKET SNAPSHOT 143 FIGURE 34 ASIA PACIFIC: HIV DIAGNOSTICS MARKET SNAPSHOT 170 FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2021−2023 (USD MILLION) 206 FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET (2023) 207 FIGURE 37 RANKING OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2023 209 FIGURE 38 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 210 FIGURE 39 HIV DIAGNOSTICS MARKET: COMPANY FOOTPRINT 211 FIGURE 40 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 215 FIGURE 41 EV/EBITDA OF KEY VENDORS 217 FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 217 FIGURE 43 HIV DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 218 FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2023) 223 FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023) 228 FIGURE 46 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023) 232 FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023) 236 FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 241 FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 246 FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 249

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們